{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:51:15Z","timestamp":1790034675176,"version":"4.0.1"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004720","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000}}],"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV010563"],"award-info":[{"award-number":["INV010563"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 AI134413"],"award-info":[{"award-number":["K24 AI134413"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Timely response to treatment failure is critical for improved outcomes and viral re-suppression among people living with HIV, but care gaps along the treatment failure cascade can occur due to delays by both clients (e.g., retention and adherence) and health systems (e.g., fidelity to viral load [VL] monitoring guidelines). We used multistate analysis to identify drivers of implementation gaps in the treatment failure cascade, including time to HIV VL monitoring, re-suppression, and regimen switches, in Zambia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>We used national electronic HIV health records to identify adults on antiretroviral therapy (ART) for more than 6 months who experienced treatment failure (VL\u2009\u2265\u20091,000 copies\/ml) at 24 clinics in Lusaka, Zambia, between August 2019 and November 2021. Using multistate analyses, we examined how care evolved after treatment failure, accounting for transitions across the treatment failure cascade over time, such as return visits, repeat VL testing, treatment interruptions (&gt;60 days late for visit), and viral re-suppression. Analyses were stratified by ART regimen at cohort entry: tenofovir disoproxil fumarate\/lamivudine or emtricitabine\/dolutegravir TDF\/XTC\/DTG (TLD) and tenofovir disoproxil fumarate\/lamivudine or emtricitabine\/efavirenz TDF\/XTC\/EFV (TLE). We repeated analyses to assess switch to second-line therapy among those with consecutively unsuppressed VL test results who were due for regimen switch. Among 179,855 individuals on ART (143,857 with documented VL), 7,916 (4.4%) had a documented elevated VL and drug regimen at the time of treatment failure (52.3% female, median age was 36.7 years (IQR 29.9\u201343.6), median time on ART 3.3 years (IQR 1.7\u20136.6), 54.6% on TLD and 45.4% on TLE). Among those with treatment failure, 72.2% (CI 71.3, 73.0%) had returned to clinic 6 months after initial elevated VL was drawn. After one year, 70.1% (CI 69.3, 70.9%) had a repeat VL, 16.6% (CI 15.9, 17.2%) experienced treatment interruption, and 11.4% (CI 10.3, 12.4%) returned to care without repeat VL testing. Among those with a repeat VL, 85.0% (CI 83.9, 86.1%) on TLD and 58.2% (CI 56.8, 59.8%) on TLE had resuppressed. Among those due for second-line switch, 27.9% (CI 24.1, 31.5%) on TLD and 66.6% (CI 64.5, 68.9%) on TLE had changed regimens after one year while 52.4% on TLD had a third VL repeated prior to switch (CI 47.2, 57.4%) (68.0% CI 61.6, 75.2% suppressed of those with repeated VL) compared to 32.1% (CI 29.9, 34.1%) (40.7% CI 36.1, 45.4% suppressed) on TLE. This study was limited by the inability to capture all aspects of care delivery related to treatment failure, such as outreach, enhanced adherence counseling confirmation, and provider rationale for delayed VL rechecking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>After treatment failure, we identified substantial delays in returning for adherence counseling, treatment interruptions, and missed opportunities in rechecking VL status or switching to second-line therapy in routine care in Zambia. Among those who did have VL tests rechecked, re-suppression rates were significantly higher among individuals on TLD compared to TLE. To optimize response and outcomes after treatment failure, strategies must prioritize and target both client and health systems behaviors to meet the care needs in the modern era of TLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004720","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T17:55:16Z","timestamp":1756922116000},"page":"e1004720","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identifying care gaps along the HIV treatment failure cascade: A multistate analysis of viral load monitoring, re-suppression, and regimen switches in Zambia"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-8661","authenticated-orcid":true,"given":"Kombatende","family":"Sikombe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8906-6879","authenticated-orcid":true,"given":"Noelle","family":"Le Tourneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5416-8058","authenticated-orcid":true,"given":"Brian","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6312-4420","authenticated-orcid":true,"given":"Jake M.","family":"Pry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Simbeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4731-7828","authenticated-orcid":true,"given":"Laura K.","family":"Beres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5757-6858","authenticated-orcid":true,"given":"Njekwa","family":"Mukamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Wringe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Hargreaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-0645","authenticated-orcid":true,"given":"Jacob","family":"Mutale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9103-7746","authenticated-orcid":true,"given":"Carolyn Bolton","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-2607","authenticated-orcid":true,"given":"Izukanji","family":"Sikazwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-365X","authenticated-orcid":true,"given":"Aaloke","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"pmed.1004720.ref001","author":"World Health Organization","year":"2021"},{"key":"pmed.1004720.ref002","unstructured":"Ministry of Health Zambia. 2022 Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection. 2022. Available from: https:\/\/www.differentiatedservicedelivery.org\/wp-content\/uploads\/August-2022-Zambia-Consolidated-Guidelines.pdf"},{"issue":"4","key":"pmed.1004720.ref003","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab086","article-title":"Participants on dolutegravir resuppress human immunodeficiency virus RNA after virologic failure: updated data from the ADVANCE trial","volume":"73","author":"T Pepperrell","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pmed.1004720.ref004","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000003385","article-title":"Viremia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy","volume":"95","author":"J Dorward","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"pmed.1004720.ref005","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25415","article-title":"HIV viral resuppression following an elevated viral load: a systematic review and meta-analysis","volume":"22","author":"N Ford","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"pmed.1004720.ref006","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0b013e31829f05ac","article-title":"Viral load monitoring as a tool to reinforce adherence: a systematic review","volume":"64","author":"K Bonner","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pmed.1004720.ref007","unstructured":"Venter F SSBB. Virological failure and HIV RNA re-suppression rates in four randomised trials of dolutegravir, efavirenz or protease inhibitor-based treatment in 3116 participants. In: International Congress on Drug Therapy in HIV Infection. 2022;abstract O42. Available from: https:\/\/www.natap.org\/2022\/Glascow\/GLASGOW_37.htm"},{"issue":"7","key":"pmed.1004720.ref008","article-title":"Forgiveness of dolutegravir-based triple therapy compared with older antiretroviral regimens: a prospective multicenter cohort of adherence patterns and HIV-RNA replication","volume":"8","author":"J-J Parienti","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"pmed.1004720.ref009","volume-title":"WHO HIV policy adoption and implementation status in countries WHO global HIV programme","author":"World Health Organization","year":"2022"},{"issue":"10","key":"pmed.1004720.ref010","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25194","article-title":"Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second-line switches in Swaziland","volume":"21","author":"D Etoori","year":"2018","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"pmed.1004720.ref011","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/hiv.12877","article-title":"Clinical outcomes after first-line HIV treatment failure in South Africa: the next cascade of care","volume":"21","author":"CC Iwuji","year":"2020","journal-title":"HIV Med"},{"issue":"4","key":"pmed.1004720.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0284996","article-title":"Exploring barriers to switching \u201con time\u201d to second-line antiretroviral therapy among nurses in primary health care facilities, Ekurhuleni Health District, South Africa","volume":"18","author":"IS Tenza","year":"2023","journal-title":"PLoS One"},{"issue":"2","key":"pmed.1004720.ref013","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1191\/0962280202SM276ra","article-title":"Multi-state models for event history analysis","volume":"11","author":"PK Andersen","year":"2002","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"pmed.1004720.ref014","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cmpb.2010.01.001","article-title":"The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models","volume":"99","author":"LC de Wreede","year":"2010","journal-title":"Comput Methods Programs Biomed"},{"issue":"7","key":"pmed.1004720.ref015","first-page":"1","article-title":"mstate: an R package for the analysis of competing risks and multi-state models","volume":"38","author":"L.C de Wreede","year":"2011","journal-title":"J Stat Softw"},{"issue":"10","key":"pmed.1004720.ref016","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa268","article-title":"Longitudinal care cascade outcomes among people eligible for antiretroviral therapy who are newly linking to care in Zambia: a multistate analysis","volume":"71","author":"A Mody","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pmed.1004720.ref017","unstructured":"Ministry of Health Zambia. Zambia Population-based HIV Impact Assessment (ZAMPHIA) 2021: Final Report. 2023. Available from: https:\/\/nada.zamstats.gov.zm\/index.php\/catalog\/1"},{"key":"pmed.1004720.ref018","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. WHO Guidelines","author":"WHO (World Health Organization)","year":"2013"},{"key":"pmed.1004720.ref019","first-page":"141","article-title":"Aalen and S\u00f8ren Johansen. An empirical transition matrix for non-homogeneous Markov chains based on censored observations on","volume":"5","author":"O Odd","year":"1978","journal-title":"Scand J Stat"},{"key":"pmed.1004720.ref020","volume-title":"Stata: Release 17. Statistical Software","author":"StataCorp","year":"2021"},{"issue":"1","key":"pmed.1004720.ref021","article-title":"Mitigating the effects of COVID-19 on HIV treatment and care in Lusaka, Zambia: a before-after cohort study using mixed effects regression","volume":"7","author":"JM Pry","year":"2022","journal-title":"BMJ Glob Health"},{"issue":"2","key":"pmed.1004720.ref022","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/QAI.0000000000002549","article-title":"Expanding the vision for differentiated service delivery: a call for more inclusive and truly patient-centered care for people living with HIV","volume":"86","author":"P Ehrenkranz","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"pmed.1004720.ref023","doi-asserted-by":"crossref","first-page":"296","DOI":"10.9745\/GHSP-D-20-00532","article-title":"Differentiated service delivery models for HIV treatment in Malawi, South Africa, and Zambia: a landscape analysis","volume":"9","author":"A Huber","year":"2021","journal-title":"Glob Health Sci Pract"},{"key":"pmed.1004720.ref024","author":"Ministry of Health Zambia","year":"2018"},{"issue":"3","key":"pmed.1004720.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003959","article-title":"Evaluation of HIV treatment outcomes with reduced frequency of clinical encounters and antiretroviral treatment refills: A systematic review and meta-analysis","volume":"19","author":"N Le Tourneau","year":"2022","journal-title":"PLoS Med"},{"issue":"1","key":"pmed.1004720.ref026","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(17)30211-4","article-title":"Point-of-care viral load testing and differentiated HIV care","volume":"5","author":"J Dorward","year":"2018","journal-title":"Lancet HIV"},{"issue":"8","key":"pmed.1004720.ref027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002918","article-title":"Correction: Retention and viral suppression in a cohort of HIV patients on antiretroviral therapy in Zambia: Regionally representative estimates using a multistage-sampling-based approach","volume":"16","author":"I Sikazwe","year":"2019","journal-title":"PLoS Med"},{"issue":"2","key":"pmed.1004720.ref028","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/cid\/cix756","article-title":"Improved retention with 6-month clinic return intervals for stable human immunodeficiency virus-infected patients in Zambia","volume":"66","author":"A Mody","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pmed.1004720.ref029","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s13063-023-07322-z","article-title":"Protocol for an evaluation of adherence monitoring and support interventions among people initiating antiretroviral therapy in Cape Town, South Africa-a multiphase optimization strategy (MOST) approach using a fractional factorial design","volume":"24","author":"L Jennings","year":"2023","journal-title":"Trials"},{"issue":"12","key":"pmed.1004720.ref030","article-title":"Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries","volume":"8","author":"WM Han","year":"2021","journal-title":"Lancet HIV"},{"issue":"7","key":"pmed.1004720.ref031","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1501","article-title":"Patient-reported reasons for stopping care or switching clinics in Zambia: A multisite, regionally representative estimate using a multistage sampling-based approach in Zambia","volume":"73","author":"I Sikazwe","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pmed.1004720.ref032","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1186\/s12913-022-08373-9","article-title":"Adherence challenges and opportunities for optimizing care through enhanced adherence counseling for adolescents with suspected HIV treatment failure in Kenya","volume":"22","author":"MM Gill","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"pmed.1004720.ref033","article-title":"Toward an understanding of disengagement from HIV treatment and care in sub-Saharan Africa: a qualitative study","volume":"10","author":"NC Ware","year":"2013","journal-title":"PLoS Med"},{"issue":"5","key":"pmed.1004720.ref034","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-001007","article-title":"\u201cThey care rudely!\u201d: resourcing and relational health system factors that influence retention in care for people living with HIV in Zambia","volume":"3","author":"C Mwamba","year":"2018","journal-title":"BMJ Glob Health"},{"key":"pmed.1004720.ref035","first-page":"1","article-title":"Negative clinic experiences as a barrier to care for people with HIV and their impact on patient preferences for intervention support: a qualitative study in Cape Town, South Africa","author":"C Killian","year":"2024","journal-title":"AIDS Care"},{"issue":"1","key":"pmed.1004720.ref036","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(24)00264-9","article-title":"Effect of a multicomponent, person-centred care intervention on client experience and HIV treatment outcomes in Zambia: a stepped-wedge, cluster-randomised trial","volume":"12","author":"K Sikombe","year":"2025","journal-title":"Lancet HIV"},{"key":"pmed.1004720.ref037","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000002216","article-title":"Human-centered design lessons for implementation science: improving the implementation of a patient-centered care intervention","volume":"82","author":"LK Beres","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"pmed.1004720.ref038","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1186\/s12879-024-09888-8","article-title":"Adherence of healthcare providers to Enhanced Adherence Counseling (EAC) intervention protocol in West Amhara Public Health Facilities, Northwest Ethiopia, 2023: mixed method evaluation","volume":"24","author":"A Belete","year":"2024","journal-title":"BMC Infect Dis"},{"key":"pmed.1004720.ref039","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1748-5908-4-29","article-title":"Development of a theory of implementation and integration: Normalization Process Theory","volume":"4","author":"CR May","year":"2009","journal-title":"Implement Sci"},{"key":"pmed.1004720.ref040","doi-asserted-by":"crossref","first-page":"918874","DOI":"10.3389\/frhs.2022.918874","article-title":"\u201cProvider discretionary power practices to support implementation of patient-centered HIV care in Lusaka, Zambia\u201d","volume":"2","author":"C Mwamba","year":"2022","journal-title":"Front Health Serv"},{"issue":"12","key":"pmed.1004720.ref041","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad583","article-title":"Clinical outcomes after viremia among people receiving dolutegravir vs efavirenz-based first-line antiretroviral therapy in South Africa","volume":"10","author":"K Asare","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"pmed.1004720.ref042","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1097\/QAD.0000000000003956","article-title":"Longitudinal viral load outcomes of adults with HIV after detectable viremia on tenofovir, lamivudine, and dolutegravir","volume":"38","author":"O Sodeke","year":"2024","journal-title":"AIDS"},{"issue":"11","key":"pmed.1004720.ref043","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(23)00228-X","article-title":"HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis","volume":"10","author":"T Loosli","year":"2023","journal-title":"Lancet HIV"},{"issue":"8","key":"pmed.1004720.ref044","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(22)00136-9","article-title":"Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study","volume":"9","author":"B Schramm","year":"2022","journal-title":"Lancet HIV"},{"key":"pmed.1004720.ref045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jclinepi.2022.02.005","article-title":"Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis","volume":"148","author":"A Hauser","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"pmed.1004720.ref046","first-page":"35","article-title":"Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era","author":"SM McCluskey","year":"2021","journal-title":"AIDS"},{"key":"pmed.1004720.ref047","article-title":"Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long acting cabotegravir for HIV treatment: A meta-analysis","author":"A Perez Navarro","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pmed.1004720.ref048","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(22)00092-3","article-title":"Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial","volume":"9","author":"NI Paton","year":"2022","journal-title":"Lancet HIV"},{"issue":"4","key":"pmed.1004720.ref049","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV","volume":"385","author":"NI Paton","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"pmed.1004720.ref050","article-title":"Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b\/4 trial","volume":"11","author":"D2EFT Study Group","year":"2024","journal-title":"Lancet HIV"},{"issue":"12","key":"pmed.1004720.ref051","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.7326\/M21-2229","article-title":"Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa\u00a0: An Unblinded Randomized Controlled Trial","volume":"174","author":"MJ Siedner","year":"2021","journal-title":"Ann Intern Med"},{"issue":"8","key":"pmed.1004720.ref052","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(25)00068-2","article-title":"Evaluation of antiretroviral regimen switching options in adults with HIV with sustained viral load non-suppression on dolutegravir, lamivudine, and tenofovir in eastern, central, southern, and western Africa: a modelling study","volume":"12","author":"AN Phillips","year":"2025","journal-title":"Lancet HIV"},{"issue":"1","key":"pmed.1004720.ref053","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5588\/pha.19.0068","article-title":"Effects of real-time electronic data entry on HIV programme data quality in Lusaka, Zambia","volume":"10","author":"K Moomba","year":"2020","journal-title":"Public Health Action"},{"issue":"11","key":"pmed.1004720.ref054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241477","article-title":"Understanding patient transfers across multiple clinics in Zambia among HIV infected adults","volume":"15","author":"K Sikombe","year":"2020","journal-title":"PLoS One"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004720","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T17:57:18Z","timestamp":1757527038000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004720"}},"subtitle":[],"editor":[{"given":"Marie-Louise","family":"Newell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004720","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}